We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Novel diarylpyrimidine subtypes as HIV‐1 nonnucleoside reverse transcriptase inhibitors with improved resistance profile.
- Authors
Wang, Zhengqiang
- Abstract
This article discusses the development of novel diarylpyrimidine subtypes as HIV-1 nonnucleoside reverse transcriptase inhibitors (NNRTIs) with improved resistance profiles. The article explains that the virally encoded reverse transcriptase (RT) is a target for HIV drugs, and while nucleos(t)ide RT inhibitors (NRTIs) and first-generation NNRTIs have been approved, RT RNase H has not been targeted. The second-generation NNRTIs, including dapivirine (DPV), have shown improved resistance profiles. The article then focuses on a recent study that identified analog 11b1 as a potent NNRTI with exceptional potency and resistance profile, validating the new DAPY subtype as an important chemical platform for developing improved DAPY NNRTIs.
- Subjects
REVERSE transcriptase inhibitors; EMTRICITABINE; HIV protease inhibitors; HIV; NON-nucleoside reverse transcriptase inhibitors
- Publication
Journal of Medical Virology, 2024, Vol 96, Issue 3, p1
- ISSN
0146-6615
- Publication type
Article
- DOI
10.1002/jmv.29553